A Cancer & Metabolism study reports that SENP1 drives de novo cholesterol synthesis in prostate cancer by deSUMOylating SREBP2 and disrupting its interaction with FBXW7, stabilizing SREBP2. The work connects a post-translational regulation axis to lipid metabolism rewiring in tumor cells. For drug discovery teams, SENP1 sits at the intersection of epigenetic/protein-modification biology and metabolic vulnerability. If the pathway proves targetable in vivo, SENP1 inhibition could become a mechanism-based approach to reduce cholesterol-dependent oncogenic functions. The next step is likely validation in model systems that incorporate pharmacokinetics and tumor microenvironment effects, including demonstrating whether pathway suppression translates into tumor growth inhibition or radiosensitization/chemosensitization potential.